The cancer-research community has long recognized lysophosphatidic acid (LPA) as a significant contributor to cancer through its promotion of cancer-cell growth and metastasis in a broad range of tumor types.
According to the company, many academics, biotechs, and pharmaceutical companies have all tried-without success-to produce drugs, including antibodies, which target LPA and neutralize its potent tumorigenic effects.
Lpath generated its monoclonal antibodies against LPA using its proprietary ImmuneY2 technology. The company also demonstrated, using standard assays, that these antibodies mitigate LPA’s tumorigenic effects on cancer cells.
“Now that we’ve established that ImmuneY2 works for the LPA project we are at a turning point where we can follow the more predictable and well-defined path of selecting the best-performing LPA antibodies to advance into development,” said Scott Pancoast, Lpath’s president and CEO.